This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
by Zacks Equity Research
BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.
BIIBNegative Net Change LLYPositive Net Change IONSNegative Net Change
biotechs
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
by Zacks Equity Research
SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.
SMMTPositive Net Change NBIXNegative Net Change AMRNNegative Net Change LQDAPositive Net Change
biotechs
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi
by Zacks Equity Research
BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.
BIIBNegative Net Change LLYPositive Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
by Zacks Equity Research
Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.
AGENPositive Net Change NVAXNegative Net Change LQDAPositive Net Change
biotechs medical
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
by Zacks Equity Research
BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.
BMRNNegative Net Change ASNDPositive Net Change BBIOPositive Net Change
biotechs
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
by Ekta Bagri
BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.
BMYPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
by Zacks Equity Research
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
GSKNegative Net Change NBIXNegative Net Change ANABPositive Net Change LQDAPositive Net Change
biotechs
Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?
by Ekta Bagri
LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.
LQDAPositive Net Change JNJPositive Net Change UTHRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Best Momentum Stocks to Buy for July 13th
by Zacks Equity Research
SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
SNDKNegative Net Change LIONPositive Net Change PTGXPositive Net Change
biotechs
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
by Zacks Equity Research
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
CGONPositive Net Change NBIXNegative Net Change AMRNNegative Net Change LQDAPositive Net Change
biotechs